Monitoring of Sarcoidosis

Vasileios Kouranos; Athol Umfrey Wells

doi:10.1016/j.ccm.2023.08.002

Monitoring of Sarcoidosis

Clin Chest Med. 2024 Mar;45(1):45-57. doi: 10.1016/j.ccm.2023.08.002. Epub 2023 Sep 4.

Authors

Vasileios Kouranos¹, Athol Umfrey Wells²

Affiliations

¹ Interstitial Lung Disease/Sarcoidosis Unit, Royal Brompton Hospital, Sydney street, London, SW3 6NP; National Heart and Lung Institute, Imperial College London, Guy Scadding Building, Cale Street, London, SW3 6LY. Electronic address: v.kouranos@rbht.nhs.uk.
² Interstitial Lung Disease/Sarcoidosis Unit, Royal Brompton Hospital, Sydney street, London, SW3 6NP; National Heart and Lung Institute, Imperial College London, Guy Scadding Building, Cale Street, London, SW3 6LY.

PMID: 38245370
DOI: 10.1016/j.ccm.2023.08.002

Abstract

This article focuses on the monitoring of pulmonary sarcoidosis. The monitoring of sarcoidosis is, in part, focused on serial change in major organ involvement but also includes diagnostic re-evaluation and review of change in quality of life. Recent criteria for progression of fibrotic interstitial lung disease are adapted to pulmonary sarcoidosis. The frequency and nature of monitoring are discussed, integrating baseline risk stratification and strategic treatment goals. Individual variables used to identify changes in pulmonary disease severity are discussed with a focus on their flaws and the need for a multidimensional approach. Other key monitoring issues are covered briefly.

Keywords: High-resolution chest computed tomography scan; Multidisciplinary; Pulmonary function tests; Quality of life; Risk stratification.

Publication types

Review

MeSH terms

Humans
Lung
Lung Diseases, Interstitial* / diagnosis
Lung Diseases, Interstitial* / therapy
Quality of Life
Sarcoidosis* / diagnosis
Sarcoidosis* / therapy
Sarcoidosis, Pulmonary* / diagnosis